GSK shares promising results from shingles vaccine trial
The varicella zoster virus that causes shingles and chicken pox is typically present in over 90% of adults globally
Read More
Tag: Shingrix
GSK’s shingles vaccine Shingrix gains UK license
Jab aimed at adults aged 50 years and older and those at increased risk
Read More
GSK posts Q4 profit
GlaxoSmithKline (GSK) has released its fourth-quarter 2018 results, reporting prescription drug sales of £4.8 billion – a 6% increase on the prior year period – and profit of £1.4 billion, marking an increase of £442 million.
Read More
GSK narrows earnings guidance after Shingrix boost
GSK says it now expects full-year earnings at the upper end of its guidance after continued sales growth during the third quarter and the delay to generic competition for one of its key products.
Read More
GSK ups guidance and unveils major restructure
GlaxoSmithKline has upped its expectations for the year after a strong performance by its vaccines division in the second quarter and the delay of a potential generic version of Advair in the US.
Read More
Seven medicines leap closer to EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Read More
CDC committee favours GSK’s shingles vaccine
The US Centre for Disease Control Prevention’s Advisory Committee on Immunisation Practices (ACIP) has given its backing to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck & Co’s veteran vaccine Zostavax.
Read More
GSK bags US nod for shingles vaccine
GlaxoSmithKline’s Shingrix has been approved in the US for protection against shingles in adults aged 50 years or older.
Read More
EU filing for GSK’s shingles jab
GlaxoSmithKline has submitted its experimental shingles vaccines to European regulators, seeking approval to market its use to prevent herpes zoster (shingles) in people aged 50 years or over.
Read More
GSK presents new data backing shingles vaccine
GSK has unveiled new data for its shingles candidate vaccine Shingrix from trials assessing its co-administration with the flu vaccine, dosing schedule and quality of life.
Read More
First filing for GSK’s shingles vaccine
GlaxoSmithKline has filed Biologics License Application in the US for Shingrix, seeking approval to market the vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or over.
Read More
- Gobivaz approved across Europe as first Simponi biosimilar
- Poolbeg granted European patent for POLB 001
- TARA-002 shows strong early results in trial for paediatric lymphatic malformations
- Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
- Cellbyte raises $2.75m to slash drug launch timelines with AI
